Upside, Downside Movers in the Morning

Upside

– $CNTB +83% (Phase 2 COPD trial met its primary endpoint, reducing treatment failures by 81% and new moderate-to-severe exacerbations by 85%)

– $NAUT +16% (no clear fresh catalyst identified; unusually large, liquid premarket move)

– $CAPR +14% (new deramiocel analyses showed slower upper-limb decline in the HOPE-3 open-label extension and versus natural history)

– $BIYA +13% (first-half results showed new continuing-operations revenue and a narrower net loss)

– $SGMT +9.0% (rises ahead of today’s KOL event on 52-week Phase 3 extension data and the planned US AURORA Phase 3 trial)

– $KALA +5.3% (signs a non-binding agreement to acquire a nationwide telehealth platform for approximately $15M)

– $HPE +4.2% (no clear fresh catalyst identified; unusually large premarket move in a major liquid stock)

Downside

– $PYXS -16% (prices a public offering of up to $282.6M, adding substantial dilution and stock supply)

– $SDEV -15% (pulls back after the prior session’s outsized speculative surge)

– $CNXC -8.7% (quarterly profitability topped guidance, but Q4 sales and profit guidance came in light and the FY revenue outlook missed expectations)

S&P Short-Range Oscillator

A subscriber – ww33 – asked (in The Comments Section) for a chart on the S&P Oscillator.

Here is a one year chart, from MarketEdge!

I will work on finding a longer term chart, as requested.

Positions: None 

Baseball Trivia Question

I want to pretend I am Sarge this morning!

After last night’s thrilling Yankee win over the hated Red Sox, I have a trivia question…

Who are the all-time leaders in playoffs — pitchers that have struck out at least 10 batters and have allowed no runs?

Position: None 

More Tales From Nvidia: The Makes No Sense Edition! (Issue #255!)

This is an interesting tweet. 

Although it is AI specific with regard to OpenAI, I view it more broadly regarding the investment world these days. 

Open AI’s valuation should be going down, not up. The fundamental picture keeps getting worse.  The prior round valuations were grossly elevated to begin with. There is seemingly nothing but massive losses on the horizon. Executives are leaving in droves. They have all sorts of issues with the product, and its related risks. The CEO is a clown. The industry overall has real issues. 

We are likely looking at midterms where Democrats may gain some power (which I have stated can be viewed as a market headwind — more corporate and individual taxes, etc.), which will not be good for AI either. 

Yet no matter how much worse things look, they can somehow attempt to keep raising money at a higher valuation than the prior elevated round. 

One of their biggest investors (SoftBank) needs to keep borrowing money at elevated rates to keep funding them. It is almost as though there is an expectation that because the prior round was done at X, the next round will be done at almost 2X. 

Who is doing this, and why?  It makes no sense. The fundamental answer is the next round of financing should be done in bankruptcy court, in my view. 

Anthropic is no different with regard to how the IPO is theoretically being priced and how their business is valued. The equity markets in total seem no different now. 

It really makes no sense. It is almost like there is some sort of magical force elevating everything. I have never seen anything like this. 

Position: None

Another Marijuana Moment

As I mentioned late yesterday afternoon, the stay is procedural and I fully expect rescheduling to occur:

DEA Judge Pauses Marijuana Rescheduling Hearing As Opponents Highlight Government Report Detailing ‘Gaps’ In Federal Processes – Marijuana Moment

According to another source, President Trump is growing impatient about the slow pace of rescheduling progress:

President Trump ‘Not Happy’ With Marijuana Rescheduling Delays, Plans to Contact Attorney General and DEA Chief, Senior Adviser Says

Position: Long MSOS common (VL) and calls (M)